Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
- 12 February 2021
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 62 (9), 1278-1284
- https://doi.org/10.2967/jnumed.120.257659
Abstract
Background: PET scans using [18F]FDG and somatostatin receptor imaging agents are both used in imaging of neuroendocrine neoplasms (NENs). We have suggested the “NETPET score”, utilizing uptake of both PET tracers, as a prognostic biomarker in NENs. We previously demonstrated the effectiveness of the NETPET score in gastroenteropancreatic (GEP) NENs. Its prognostic relevance in bronchial NENs remains undetermined. Methods: This is a retrospective multicentre study (2011-2018) assessing patients who had advanced bronchial NEN and who underwent both [18F]FDG and [68Ga]Ga-DOTATATE PET within 60 days of each other. The NETPET score was assigned by experienced nuclear medicine physicians and compared with other clinical data such as WHO grade. The primary outcome was overall survival (OS); NETPET score and other prognostic variables were analysed using univariate and multivariate analyses by the Cox proportional-hazards model. Results: Thirty-eight patients were included for review. The NETPET score and histology were significantly correlated with OS in univariate analyses (P = 0.003, P = 0.01). On multivariate analysis, only the NETPET score remained significant (P = 0.03). The NETPET score was significantly associated with histological grade (P = 0.006, chi-squared test). Conclusion: The NETPET score is a prognostic biomarker in bronchial NENs as well as GEPNENs. Whilst it needs to be validated in prospective studies, it holds significant promise as a biomarker for a wide range of NENs.This publication has 25 references indexed in Scilit:
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyThe Lancet, 2015
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomesCancer, 2014
- Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC studyAnnals of Oncology, 2012
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsThe New England Journal of Medicine, 2011
- Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine TumorsClinical Cancer Research, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008